KR20200020622A - 치환된 헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 - Google Patents

치환된 헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 Download PDF

Info

Publication number: KR20200020622A
Authority: KR; South Korea
Prior art keywords: cyclopropyl; amino; pyrrolo; cancer; trifluoromethyl
Prior art date: 2018-08-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

KR1020190099553A

Other languages

English (en)

Korean (ko)

Inventor

최환근

고은화

박진희

고이경

강석용

김소영

장보미

이승연

이선화

김다예

이선주

김상범

박종배

남도현

Original Assignee

재단법인 대구경북첨단의료산업진흥재단

사회복지법인 삼성생명공익재단

국립암센터

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-08-16

Filing date

2019-08-14

Publication date

2020-02-26

2019-08-14 Application filed by 재단법인 대구경북첨단의료산업진흥재단, 사회복지법인 삼성생명공익재단, 국립암센터 filed Critical 재단법인 대구경북첨단의료산업진흥재단

2020-02-26 Publication of KR20200020622A publication Critical patent/KR20200020622A/ko

Status Ceased legal-status Critical Current

Links

WBEZSPQMQCLQBA-UHFFFAOYSA-N COc1cc(C(N(CC2)CCN2C2COC2)=O)ccc1Nc1nc([nH]cc2C(F)(F)F)c2c(C2CC2)c1 Chemical compound COc1cc(C(N(CC2)CCN2C2COC2)=O)ccc1Nc1nc([nH]cc2C(F)(F)F)c2c(C2CC2)c1 WBEZSPQMQCLQBA-UHFFFAOYSA-N 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

KR1020190099553A 2018-08-16 2019-08-14 치환된 헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 Ceased KR20200020622A (ko)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR1020180095544		2018-08-16
KR20180095544		2018-08-16

Publications (1)

Publication Number	Publication Date
KR20200020622A true KR20200020622A (ko)	2020-02-26

Family

ID=69525734

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1020190099553A Ceased KR20200020622A (ko)	2018-08-16	2019-08-14	치환된 헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물

Country Status (2)

Country	Link
KR (1)	KR20200020622A (fr)
WO (1)	WO2020036437A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2021194144A1 (fr) *	2020-03-23	2021-09-30	환인제약 주식회사	Nouveau dérivé de pyrimidine, et composition pour la prévention ou le traitement de maladies neurodégénératives et du cancer, comprenant celui-ci
WO2024035194A1 (fr) *	2022-08-11	2024-02-15	환인제약 주식회사	Nouveau dérivé substitué par hétéroaryle et composition le comprenant pour prévenir ou traiter une maladie neurodégénérative, un cancer et une maladie inflammatoire
KR20240023483A (ko) *	2022-08-11	2024-02-22	환인제약 주식회사	신규한 헤테로아릴 치환 유도체 및 이를 포함하는 신경퇴행성질환, 암, 및 염증성 질환의 예방 또는 치료용 조성물

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3148611A1 (fr)	2019-08-12	2021-02-18	Regeneron Pharmaceuticals, Inc.	Variants du recepteur 1 de la stimulation des macrophages (mst1r) et leurs utilisations
EP4238975A4 (fr) *	2020-10-29	2024-06-12	Suzhou Yabao Pharmaceutical R&D Co., Ltd.	Composé de diarylamine substitué, composition pharmaceutique de celui-ci, procédé de préparation correspondant et utilisation associée

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20160106623A (ko) *	2014-01-29	2016-09-12	글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드	화합물
MA39219B1 (fr) *	2014-01-29	2018-11-30	Glaxosmithkline Ip Dev Ltd	Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
US11214565B2 (en) *	2015-11-20	2022-01-04	Denali Therapeutics Inc.	Compound, compositions, and methods

2019
- 2019-08-14 WO PCT/KR2019/010369 patent/WO2020036437A1/fr not_active Ceased
- 2019-08-14 KR KR1020190099553A patent/KR20200020622A/ko not_active Ceased

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2021194144A1 (fr) *	2020-03-23	2021-09-30	환인제약 주식회사	Nouveau dérivé de pyrimidine, et composition pour la prévention ou le traitement de maladies neurodégénératives et du cancer, comprenant celui-ci
WO2024035194A1 (fr) *	2022-08-11	2024-02-15	환인제약 주식회사	Nouveau dérivé substitué par hétéroaryle et composition le comprenant pour prévenir ou traiter une maladie neurodégénérative, un cancer et une maladie inflammatoire
KR20240023483A (ko) *	2022-08-11	2024-02-22	환인제약 주식회사	신규한 헤테로아릴 치환 유도체 및 이를 포함하는 신경퇴행성질환, 암, 및 염증성 질환의 예방 또는 치료용 조성물

Also Published As

Publication number	Publication date
WO2020036437A1 (fr)	2020-02-20

Similar Documents

Publication	Publication Date	Title
KR102092812B1 (ko)	2020-03-25	피롤로-피리미딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
EP3778604B1 (fr)	2026-01-07	Inhibiteurs de lrrk2 et leurs méthodes de production et d'utilisation
KR102782739B1 (ko)	2025-03-20	2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
KR102901976B1 (ko)	2025-12-24	2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물
KR102297587B1 (ko)	2021-09-06	치환된 n-헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
KR20200020622A (ko)	2020-02-26	치환된 헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
KR101931435B1 (ko)	2018-12-21	신규한 이미다조피리딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
RU2551274C2 (ru)	2015-05-20	Замещенное фосфорсодержащей группой хинолиноподобное соединение, способ его получения, лекарственная композиция, содержащая это соединение, и его применение
RU2730849C1 (ru)	2020-08-26	Производное пирроло-пиридинового соединения, способ его получения и фармацевтическая композиция, содержащая его в качестве активного ингредиента, для профилактики и лечения заболеваний, связанных с протеинкиназой
KR102328435B1 (ko)	2021-11-18	신규 피리도-피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
KR102293980B1 (ko)	2021-08-26	디하이드로피라노[3,2-g]크로멘-2-온 유도체 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
KR20200006495A (ko)	2020-01-20	N-(3-(이미다조[1,2-b]피리다진-3-일에티닐)-4-메틸페닐)-5-페닐-4,5-다이하이드로-1H-피라졸-1-카복사마이드 유도체 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물
KR20200088945A (ko)	2020-07-24	벤조[b][1,4]옥사제핀 유도체 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물
KR102328423B1 (ko)	2021-11-18	신규 트리아졸로-피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
KR102286701B1 (ko)	2021-08-06	피리도[2,3-d]피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
CA2976109C (fr)	2025-07-15	Pyrrolopyrimidine substituee, pyrazolopyrimidine et derives de purine, et utilisation connexe comme inhibiteurs de lrrk2
HK40045412A (en)	2021-10-22	Lrrk2 inhibitors and methods of making and using the same
HK40044616A (en)	2021-10-08	Lrrk2 inhibitors and methods of making and using the same
KR20200105592A (ko)	2020-09-08	4-((1h-피라졸-3-일)아미노)프탈라진-1(2h)-온 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물

Legal Events

Date	Code	Title	Description
2019-08-14	PA0109	Patent application	Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20190814
2020-02-26	PG1501	Laying open of application
2022-08-04	A201	Request for examination
2022-08-04	PA0201	Request for examination	Patent event code: PA02012R01D Patent event date: 20220804 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20190814 Comment text: Patent Application
2024-10-02	E902	Notification of reason for refusal
2024-10-02	PE0902	Notice of grounds for rejection	Comment text: Notification of reason for refusal Patent event date: 20241002 Patent event code: PE09021S01D
2025-02-20	E601	Decision to refuse application
2025-02-20	PE0601	Decision on rejection of patent	Patent event date: 20250220 Comment text: Decision to Refuse Application Patent event code: PE06012S01D